SCHEMBL1908380

SCHEMBL1908380

Cn1[c]cnc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HPGDS O60760 1/20 0.40
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 2/20 0.39
HSD11B1 P28845 2/20 0.37
BACE1 P56817 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA2B P29275 1/20 0.37
ADORA1 P30542 1/20 0.37
PI4KA P42356 1/20 0.37
PI4K2B Q8TCG2 1/20 0.37
PI4K2A Q9BTU6 1/20 0.37
PI4KB Q9UBF8 1/20 0.37
MAPT P10636 2/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15201363 0.77 TP53 (0.39) NPC1RAB9AALDH1A1KMT2AHSD11B1
SCHEMBL1905526 0.75 NPC1 (0.47) NPC1RAB9AALDH1A1TSHRMAPT
SCHEMBL1904290 0.73 CYP2A6 (0.39) CYP3A4
SCHEMBL5610200 0.67 NR1H3 (0.46) NR1H2NR1H3NPC1RAB9AALDH1A1
SCHEMBL1435587 0.67 NPC1 (0.41) NR1H2NR1H3NPC1RAB9AHPGDS
SCHEMBL4391055 0.67 KMT2A (0.43) NR1H2NR1H3NPC1RAB9AALDH1A1
SCHEMBL822698 0.66 HSD11B1 (0.68) NR1H2NR1H3NPC1RAB9AALDH1A1
SCHEMBL8453399 0.64 HPGDS (0.58) NR1H2NR1H3NPC1RAB9AHPGDS
SCHEMBL786747 0.64 HDAC4 (0.52) NR1H2NR1H3NPC1RAB9AALDH1A1
SCHEMBL822672 0.64 NR1H2 (0.47) NR1H2NR1H3NPC1RAB9AHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 NR1H2 2031/4885NR1H3 2231/4885NPC1 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.